share_log

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Benzinga Real-time News ·  Sep 13, 2022 18:46
  • Akero Therapeutics(NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares traded as high as 142.3 percent, in a range of $25.01 to $29.73 on day volume of 49.46 million shares versus three months average volume of 406.52 thousand shares, closed regular trading session at $29.05. The company shares traded at $28.2, down 2.93 percent in the after-hours trading session.
  • Akouos (NASDAQ:AKUS) has received clearance from the U...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment